The need for precision medicine clinical trials in childhood asthma: Rationale and design of the PUFFIN trial

Pharmacogenomics

Volumn 18, Issue 4, 2017, Pages 393-401

  Vijverberg, Susanne J H ^a   Pijnenburg, Mariëlle W ^b   Hövels, Anke M ^c   Koppelman, Gerard H ^d,e   Maitland Van Der Zee, Anke Hilse ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR STIMULATING AGENT; ADRB2 PROTEIN, HUMAN;

ARTICLE; ASTHMA; COST UTILITY ANALYSIS; GENETIC VARIATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHARMACOGENOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); CHILD; DOUBLE BLIND PROCEDURE; GENETICS; MULTICENTER STUDY (TOPIC); PROCEDURES;

ASTHMA; CHILD; DOUBLE-BLIND METHOD; HUMANS; MULTICENTER STUDIES AS TOPIC; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ADRENERGIC, BETA-2;

EID: 85014421514     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2016-0174     Document Type: Article

References (41)

1. Global Iniative for Asthma. Global Strategy for Asthma Management and Prevention. (Update 2016). www.ginasthma.org
2. van den Akker-Van Marle ME, Bruil J, Detmar SB. Evaluation of cost of disease: Assessing the burden to society of asthma in children in the European Union. Allergy 60(2), 140-149 (2005).
3. Bahadori K, Doyle-Waters MM, Marra C et al. Economic burden of asthma: a systematic review. BMC Pulm. Med. 9(1), 24 (2009).
4. NIVEL. [Zorgsituatie van mensen met astma. Rapportage 2010]. (In Dutch). www.nivel.nl/
5. Williams AE, Lloyd AC, Watson L, Rabe KF. Cost of scheduled and unscheduled asthma management in seven European Union countries. Eur. Respir. Rev. 98 4-9 (2006).
6. Szefler SJ, Phillips BR, Martinez FD et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. 115(2), 233-242 (2005).
7. Turner S, Francis B, Vijverberg S et al. Childhood asthma exacerbations and the Arg16 beta2-receptor polymorphism: a meta-analysis stratified by treatment. J. Allergy Clin. Immunol. 138(1), 107.e105-113.e105 (2016).
8. Lipworth BJ, Basu K, Donald HP et al. Tailored second-line therapy in asthmatic children with the Arg(16) genotype. Clin. Sci. (Lond) 124(8), 521-528 (2013).
9. Lemanske RFJ, Mauger DT, Sorkness CA et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N. Engl. J. Med. 362(11), 975-985 (2010).
10. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br. Med. Bull. 56(4), 1054-1070 (2000).
11. Davis JS, Weiss ST, Tantisira KG. Asthma pharmacogenomics: 2015 update. Curr. Allergy Asthma Rep. 15(7), 42 (2015).
12. Kersten ET, Koppelman GH. Pharmacogenetics of asthma: toward precision medicine. Curr. Opin. Pulm. Med. 23(1), 12-20 (2017).
13. Farzan N, Vijverberg SJ, Arets HG, Raaijmakers JA, Maitland-van der Zee AH. Pharmacogenomics of inhaled corticosteroids and leukotriene modifiers: a systematic review. Clin. Exp. Allergy. 47(2), 271-293 (2017).
14. Park HW, Dahlin A, Tse S et al. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J. Allergy Clin. Immunol. 133(3), 664.e665-669.e665 (2014).
15. Tantisira KG, Damask A, Szefler SJ et al. Genomewide association identifies the T gene as a novel asthma pharmacogenetic locus. Am. J. Respir. Crit. Care Med. 185(12), 1286-1291 (2012).
16. Tantisira KG, Lasky-Su J, Harada M et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 365(13), 1173-1183 (2011).
17. Mosteller M, Hosking L, Murphy K et al. No evidence of large genetic effects on steroid response in asthma patients. J. Allergy Clin. Immunol. doi:http://dx.doi.org/10.1016/j. jaci.2016.05.032 (2016) (Epub ahead of print).
18. Dahlin A, Litonjua A, Irvin CG et al. Genome-wide association study of leukotriene modifier response in asthma. Pharmacogenomics J. 16(2), 151-157 (2016).
19. Dahlin A, Litonjua A, Lima JJ et al. Genome-Wide association study identifies novel pharmacogenomic loci for therapeutic response to montelukast in asthma. PloS ONE 10(6), e0129385 (2015).
20. Mougey EB, Chen C, Tantisira KG et al. Pharmacogenetics of asthma controller treatment. Pharmacogenomics J. 13(3), 242-250 (2013).
21. Rogers AJ, Tantisira KG, Fuhlbrigge AL et al. Predictors of poor response during asthma therapy differ with definition of outcome. Pharmacogenomics 10(8), 1231-1242 (2009).
22. Tantisira KG, Lake S, Silverman ES et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. 13(13), 1353-1359 (2004).
23. Koster ES, Maitland-van der Zee AH, Tavendale R et al. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. Allergy 66(12), 1546-1552 (2011).
24. Tantisira KG, Silverman ES, Mariani TJ et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J. Allergy Clin. Immunol. 120(6), 1285-1291 (2007).
25. Tantisira KG, Lima J, Sylvia J, Klanderman B, Weiss ST. 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet. Genomics 19(3), 244-247 (2009).
26. Telleria JJ, Blanco-Quiros A, Varillas D et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir. Med. 102(6), 857-861 (2008).
27. Basu K, Palmer CN, Tavendale R, Lipworth BJ, Mukhopadhyay S. Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J. Allergy Clin. Immunol. 124(6), 1188.e1183-1194.e1183 (2009).
28. Zuurhout MJ, Vijverberg SJ, Raaijmakers JA et al. Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting beta2-agonists: results of the PACMAN cohort. Pharmacogenomics 14(16), 1965-1971 (2013).
29. Wechsler ME, Kunselman SJ, Chinchilli VM et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 374(9703), 1754-1764 (2009).
30. Mcmahon AW, Levenson MS, Mcevoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved longacting β2-adrenergic receptor agonists. Pediatrics 128(5), e1147-e1154 (2011).
31. Kersten ETG, Koppelman GH, Thio BJ. Concerns with beta2-agonists in pediatric asthma-A clinical perspective. Paediatr. Resp. Rev. 21, 80-85 (2017).
32. Stempel DA, Szefler SJ, Pedersen S et al. Safety of adding salmeterol to fluticasone propionate in children with asthma. N. Engl. J. Med. 375(9), 840-849 (2016).
33. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Revised 2014 (2014). www.brit-thoracic.org.uk/
34. Liu AH, Zeiger R, Sorkness C et al. Development and crosssectional validation of the Childhood Asthma Control Test. J. Allergy Clin. Immunol. 119(4), 817-825 (2007).
35. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual. Life Res. 5(1), 35-46 (1996).
36. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in the parents of children with asthma. Qual. Life Res. 5(1), 27-34 (1996).
37. Postma DS, Wijkstra PJ, Hiemstra PS et al. The dutch national program for respiratory research. Lancet Respir. Med. 4(5), 356-357 (2016).
38. Voorend-van Bergen S, Vaessen-Verberne AA, Brackel HJ et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax 70(6), 543-550 (2015).
39. Wolowacz SE, Briggs A, Belozeroff V et al. Estimating health-state utility for economic models in clinical studies: an ISPOR Good Research Practices Task Force report. Value Health 19(6), 704-719 (2016).
40. Zorginstituut Nederland. [Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg] (2015). (In Dutch). www.zorginstituutnederland.nl
41. Hollander Z, Demarco ML, Sadatsafavi M, Mcmanus BM, Ng RT, Sin DD. Biomarker development in COPD: moving from p-values to products to impact patient care. Chest 151(2), 455-467 (2017).